Abstract: A fluidized coal mining method utilizing self-energy storage of a coal seam is provided, and includes developing a mine roadway, uncovering coal actively, mining coal in fluidization, and backfilling a goaf. Dynamic phenomenon is induced by uncovering the coal actively, a coal-mining drilling well is established from a ground to the coal seam, and the coal seam is subjected to hydraulic in-situ cutting, and a coal-rock mixture subjected to hydraulic cutting flows into a roadway system along a floor roadway, and then coal, gangue and water in the mixture are separated and recycled in a subsequent circulating coal mining process.

Abstract: Compounds for, and methods of, modeling and treating a neurodegenerative disease, including without limitation frontal temporal dementia (FTD), are provided. An effective dose of a pharmaceutical composition is administered to a patient in need thereof, where the pharmaceutical composition targets at least one muscleblind-like protein (MBNL) binding site on exon 10 of microtubule-associated protein tau (MAPT) to block MBNL binding thereto. The at least one MBNL binding site may be 2 binding sites. The pharmaceutical composition may include the nuclease-inactive dCas13d in complex, with one or more guide RNAs, and/or antisense oligonucleotides (ASOs).

Abstract: A fluidized coal mining method utilizing self-energy storage of a coal seam is provided, and includes developing a mine roadway, uncovering coal actively, mining coal in fluidization, and backfilling a goaf. Dynamic phenomenon is induced by uncovering the coal actively, a coal-mining drilling well is established from a ground to the coal seam, and the coal seam is subjected to hydraulic in-situ cutting, and a coal-rock mixture subjected to hydraulic cutting flows into a roadway system along a floor roadway, and then coal, gangue and water in the mixture are separated and recycled in a subsequent circulating coal mining process.

Abstract: A method of increasing or decreasing expression of a target mRNA and protein for treatment of certain disease conditions by cells having a pre-mRNA that comprises a poison exon and encodes the target protein, and can include contacting the cells with an antisense oligomer (ASO) complementary to a targeted portion of the pre-mRNA.

Abstract: The present invention discloses a hydrogenation catalyst comprising metallic palladium supported on activated carbon support, wherein the penetration depth of metallic palladium in the support is at least about 10 ?m and up to about 100 ?m, the crystallite size of palladium is between about 40 ? and about 120 ?, and the palladium in the surface layer from the surface of support to a depth of 1 ?m is from about 5% to about 40% based on the total atom number of palladium and other elements. The present invention further discloses a process for preparing the hydrogenation catalyst, and a use of said hydrogenation catalyst in the purification of crude terephthalic acid.

Abstract: The present invention discloses a hydrogenation catalyst comprising metallic palladium supported on activated carbon support, wherein the penetration depth of metallic palladium in the support is at least about 10 ?m and up to about 100 ?m, the crystallite size of palladium is between about 40 ? and about 120 ?, and the palladium in the surface layer from the surface of support to a depth of 1 ?m is from about 5% to about 40% based on the total atom number of palladium and other elements. The present invention further discloses a process for preparing the hydrogenation catalyst, and a use of said hydrogenation catalyst in the purification of crude terephthalic acid.